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Abstract
Background: Ergosterol peroxide (EP) derived from edible mushroom has been shown to exert anti-tumor activity
in several cancer cells. In the present study, anti-angiogenic activity of EP was investigated with the underlying
molecular mechanisms in human multiple myeloma U266 cells.
Results: Despite weak cytotoxicity against U266 cells, EP suppressed phosphorylation, DNA binding activity and
nuclear translocalization of signal transducer and activator of transcription 3 (STAT3) in U266 cells at nontoxic
concentrations. Also, EP inhibited phosphorylation of the upstream kinases Janus kinase 2 (JAK2) and Src in a time-
dependent manner. Furthermore, EP increased the expression of protein tyrosine phosphatase SHP-1 at protein
and mRNA levels, and conversely silencing of the SHP-1 gene clearly blocked EP-mediated STAT3 inactivation. In
addition, EP significantly decreased vascular endothelial growth factor (VEGF), one of STAT3 target genes at cellular
and protein levels as well as disrupted in vitro tube formation assay. Moreover, EP significantly suppressed the
growth of U266 cells inoculated in female BALB/c athymic nude mice and immunohistochemistry revealed that EP
effectively reduced the expression of STAT3 and CD34 in tumor sections compared to untreated control.
Conclusion: These findings suggest that EP can exert antitumor activity in multiple myeloma U266 cells partly with
antiangiogenic activity targeting JAK2/STAT3 signaling pathway as a potent cancer preventive agent for treatment
of multiple myeloma cells.
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Background
Ergosterol Peroxide (EP), 5a,8 a-epidioxy-22E-ergosta-6,
22-dien-3b-ol, is found in plants [1], lichens [2] and
mushrooms such as Ganoderma lucidum [3], Sporothrix
schenckii [4] and Cordyceps sinensis [5]. Despite various
biological effects of EP such as immunosuppressive
[6-8], anti-viral [9], anti-inflammatory [10] and anti-
tumor [5,10] activities, the underlying molecular
mechanisms for anti-cancer activity of EP still remain
unclear.
STAT proteins originally discovered as latent cytoplas-
mic transcription factors [11] are involved in a variety of
cellular processes such as cell proliferation, differentia-
tion and apoptosis [12,13]. Of the STAT proteins,
STAT3 is often constitutively activated in many human
cancer cells including multiple myeloma, leukemia, lym-
phoma, and solid tumors [14,15]. Upon activation,
STAT3 undergoes phosphorylation-induced homodi-
merization, leading to nuclear translocation, DNA bind-
ing and subsequent gene transcription. STAT3
phosphorylation is mediated through the activation of
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kinases (JAKs) and c-Src [16].
STAT3 participates in oncogenesis through up-regula-
tion of genes encoding apoptosis inhibitors such as bcl-
xL, bcl-2, and survivin [15]. Also, recent studies reported
the evidences that STAT3 is involved in the regulation
of angiogenesis through modulation of VEGF, a key reg-
ulator of angiogenesis [17-19]. In this regards, we inves-
tigated anti-angiogenic effect of EP in association with
JAK2/STAT3 pathway and STAT3 related VEGF expres-
sion in U266 cells in vitro and mouse xenograft model.
Methods
Isolation of ergosterol peroxide (EP)
EP was isolated according to the Krzyczkowski’s method
as previously described [20].
Cell culture
U266 (multiple myeloma), SCC4 (head and neck squa-
mous cell carcinoma), DU145 (prostate cancer), and
MDA-MB-231 (breast cancer) cells were obtained from
American Type Culture Collection (ATCC) (Rockville,
MD) and maintained in RPMI 1640 supplemented with
10% FBS and antibiotics. Human umbilical vein
endothelial cells (HUVECs) were isolated from fresh
human umbilical cord vein by collagenase treatment as
described previously [21]. The cells were maintained in
in EBM-2 containing 2% FBS, 0.04% hydrocortisone,
0.4% hFGF-B, 0.1% VEGF, 0.1% IGF-1, 0.1% ascorbic
acid, 0.1% hEGF, 1% GA-1000, and 1% Heparin (Walk-
ersville, MD)
Cytotoxicity assay
The cytotoxic effect of EP was evaluated by 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. U266 cells were seeded onto 96-well micro-
p l a t ea tad e n s i t yo f1×1 0
4 cells/well and treated with
various concentrations of EP (0, 6.25, 12.5, 25 or 50 μM)
for 24 h. The culture medium was removed after centri-
fuging the plate and MTT solution (1 mg/ml) was added
to each well until formazan was constituted. MTT lysis
solution (20% SDS and 50% dimethylfermamide) was
added to dissolve formazan and optical density (OD) was
measured using microplate reader (Tecan Austria
GmbH, Grödig, Austria) at 570 nm. Cell viability was cal-
culated as a percentage of viable cells in EP-treated
group versus untreated control by following equation.
Cell viability(%) =

OD (EP) − OD (Blank)

/

OD (Control) − OD(Blank)

×100
Western blotting
Cells lysates were prepared using lysis buffer [50 mM
Tris (pH 7.4), 300 mM NaCl, 5 mM EDTA (pH 8.0),
0.5% Triton X-100, 1 mM aprotinin, 1 mM leupeptin, 1
mM pepstatin, 10 mM iodoacetamide, 2 mM phenyl-
methylsulfonyl fluoride (PMSF), and 1 mM NaVO4] and
centrifuged at 14, 000 × g for 10 min at 4°C. Protein
samples were collected, separated onto 10-12% SDS-
PAGE gels and electrotransferred to a nitrocellulose
membrane. The membranes were blocked in 5% nonfat
skim milk, probed with primary antibodies for STAT3,
phospho-STAT3
Y705, JAK2, phospho-JAK2
Y1007/1008, Src,
phospho-Src
Y416 ( C e l lS i g n a l i n g ,D a n v e r s ,M A ) ,S H P - 1 ,
VEGF (Santa Cruz Biotechnology, Santa Cruz, CA) and
b-actin (Sigma, St. Louis, MO) at 4°C for overnight, and
then exposed to HRP-conjugated secondary antibodies
at room temperature for 2 h. Protein expression was
detected by using enhanced chemiluminescence (ECL)
kit (Amersham Pharmacia, Piscataway, NJ).
Electrophoretic mobility shift assay (EMSA) for STAT3-
DNA binding
The STAT3-DNA binding was analyzed by electro-
phoretic mobility shift assay (EMSA) using a
32P-labeled
high-affinity sis-inducible element (hSIE) probe (5’-
CTTCATTTCCCGTAAATCCCTAAAGCT-3’ and 5’-
AGCTTTAGGGATTTACGG GAAA TGA-3’)a sp r e -
viously described [22]. Briefly, nuclear extracts were
incubated with the hSIE probe and the protein-DNA
complexes were separated onto 5% native polyacryla-
mide gels. The gels were dried, and the radioactive
bands were quantitated with Storm 820 and Imagequant
software (Amersham Pharmacia, Piscataway, NJ).
RT-PCR analysis
Total RNA was extracted by using Trizol reagent (Invi-
trogen) according to the manufacturer’s instructions.
cDNA was synthesized from 1 μgo ft o t a lR N Aa n ds u b -
jected to PCR reaction by using Superscript One Step
reverse transcription-PCR (RT-PCR) kit (Invitrogen).
The PCR conditions were 30 cycles of 94°C for 15 s, 55°C
for 30 s, and 72°C for 1 min. The primer sequences were
as follows: SHP-1 (forward primer 5’-AAT GCG TCC
CAT ACT GGC CCG A-3’; reverse primer 5’-CCC GCA
GTT GGT CAC AGA GT-3’), and GAPDH (forward pri-
mer 5’-TCA CCA TCT TCC AGG AGC GA-3’; reverse
primer 5’-CAC AAT GCC GAA GTG GTG GT-3’).
siRNA transfection
siRNA oligonucleotides for SHP-1 (SantaCruz biotech-
nology, SantaCruz, CA) were transfected by using Lipo-
fectAMINE transfection reagent (Invitrogen, Carlsbad,
CA) according to manufacturer’s protocols.
Enzyme- linked immunosorbent assay (ELISA) for VEGF
U266 cells were seeded onto 6-well plates at a density of
1×1 0
6 cells/well and treated with 25 μME P .T h e
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a Quantikine VEGF ELISA kit (R&D systems, Minnea-
polis, MN) according to manufacturer’s protocols.
In vitro tube formation assay
Tube formation assay was performed on Matrigel (Bec-
ton Dickinson Labware, Bedford, MA) as described pre-
viously [23]. In brief, human umbilical vein endothelial
cells (HUVECs) (3 × 10
4 cells/well) were seeded onto
Matrigel-coated 24-well plates and treated with VEGF
(20 ng/ml) in the absence or presence of EP (0, 10 or 25
μM) for 6 h. Cells were fixed with 2% paraformaldehyde
and stained with 2% crystal violet. Tube formation was
observed under an Axiovert S 100 light microscope
(Carl Zeiss, Weimar, Germany) and counted in ran-
domly selected areas using NIH Scion image program.
Mouse xenograft model
Six-week-old female athymic nude mice were purchased
from Jung Ang lab animal (Seoul, Republic of Korea)
and maintained under conventional conditions. U266
cells (2 × 10
6 cells) were mixed with Matrigel (Becton
Dickinson, 50%, in 100 μl) and injected subcutaneously
on the right flank of the mice. After 5 days of inocula-
tion, the mice (n = 5/group) were given intraperitonial
(i.p) injection of EP at 100 mg/Kg in 2% tween-80, or
bortezomib i.p.0 . 2 5m g / k gi nP B Se v e r y2o r3d a y s .
Control mice were administered the solvent vehicle.
Tumor volume was measured every other day with cali-
per and calculated according to the formula; V =
0.25a
2b, where a is the smallest superficial diameter and
b is the largest superficial diameter.
Immunohistochemistry
The animals were sacrificed 20 days after U266 inocula-
tion, and tumors were immediately removed, fixed in
4% paraformaldehyde, paraffin-embedded, and sectioned
at 4 μm. Immunohistochemical staining for phospho-
STAT3(Cell Signaling Technology, Danvers, MA), CD
34 (microvessel marker, Abcam, Boston, MA) and
TUNEL (Calbiochem, Darmstadt, Germany) was per-
formed and detected by DAB substrate staining (brown).
Statistical analysis
All values were expressed as means ± S.D. Data were
analyzed by one-way analysis of variance (ANOVA) and
by student’s t-test (Sigma plot
®, San Rafael, CA, USA).
Results
Ergosterol peroxide suppresses STAT3 activation in U266
cells
STAT3 is implicated in cell survival and growth in mul-
tiple myeloma cells [14]. In light of this event, we exam-
ined whether EP can modulate the constitutive
activation of STAT3 in U266 cells. EP significantly
inhibited the constitutive activation of STAT3 in time-
and dose-dependent manners (Figure 1A and 1B,
respectively). Tyrosine phosphorylation of STATs causes
their dimerization and translocation to the nucleus,
where they bind to DNA and regulate gene transcription
[22]. Furthermore, we evaluated whether EP can affect
on constitutive STAT3 activation in other cancer cell
lines. SCC4 (head and neck squamous cell carcinoma),
DU145 (prostate cancer), and MDA-MB-231 (breast
cancer) cells expressing constitutive STAT3 were treated
with or without EP. As shown in Figure 1C, EP inhibited
STAT3 activation without affecting total STAT3 level.
Consistent with the results of Western blotting in Figure
1A and 1B, gel shift assay showed that EP clearly inhib-
ited the STAT3 DNA-binding activity in time- and
dose-dependent manners (Figure 1D and 1E,
respectively).
Ergosterol peroxide suppresses JAK2 and Src in U266
cells
STAT3 is activated by soluble tyrosine kinases JAKs
[24]. Effect of EP was measured on the activation of
JAK2 by Western blotting. EP suppressed the phosphor-
y l a t i o no fJ A K 2i nat i m e - d e p e n d e n tm a n n e r( F i g u r e
2A), while it did not change the level of JAK1 (data not
shown). The Src is another tyrosine kinase family to
activate STAT3 signaling [16]. EP also decreased the
phosphorylation of Src in a time-dependent manner
(Figure 2B). These results indicate that EP inactivates
the upstream kinases JAK2 and Src of STAT3 in U266
cells.
Ergosterol peroxide enhances expression of SHP-1 in
U266 cells
Non-transmembrane protein tyrosine phosphatases
(PTPs) play important roles in the negative regulation of
the JAK/STAT signaling [25]. Thus, we investigated
whether PTPs are involved in EP-mediated STAT3 inac-
tivation using a PTP inhibitor sodium pervanadate. As
shown in Figure 3A, pervanadate reversed EP-induced
STAT3 inactivation in a dose-dependent manner, indi-
cating the important role of PTP(s) in EP induced
STAT3 inactivation in U266 cells.
Since SHP-1 is a PTP expressed most abundantly in
hematopoietic cells [26,27], the effect of EP on the
expression of SHP-1 was examined. EP enhanced SHP-1
protein expression in time- and dose-dependent man-
ners (Figure 3B and 3C). Consistently, EP increased the
expression of SHP-1 at the mRNA level in a time-
dependent manner (Figure 3D). Conversely, EP-
m e d i a t e dS H P - 1w a sr e d u c e di nat i m ec o u r s eb yt h e
removal of EP containing media, indicating that SHP-1
expression by EP is reversible (Figure 3E). Furthermore,
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abolishes the ability of EP to inhibit STAT3 while
scrambled siRNA had no effect on the expression (Fig-
ure 3F). Taken together, these results showed evidence
that SHP-1 plays a critical role in the suppression of
STAT3 phosphorylation by EP.
Ergosterol peroxide (EP) exerts anti-angiogenic activity in
vitro
Cytotoxicity of EP against U266 cells were determined
by MTT assay. U266 cells were treated with various
concentrations of EP (0, 6.25, 12.5, 25 or 50 μM) for
24 h. As shown in Figure 4A, EP had no significant
cytotoxic effect in U266 cells. STAT3 contributes to
angiogenic regulation by inducing VEGF expression
[28,29]. Thus, VEGF protein expression was analyzed
at the cellular and protein levels in EP-treated cells.
EP suppressed protein expression of VEGF in a time-
dependent manner by Western blotting (Figure 4B).
Consistently, secretion of VEGF was significantly
inhibited by EP treatment in time- and dose-depen-
dent manners by ELISA (Figure 4C and 4D,
respectively).
To further confirm the anti-angiogenic activity of EP,
in vitro tube formation assay was conducted using
HUVECs treated either with or without VEGF in the
absence or presence of EP. As shown in Figure 4E, no
tube formation was observed in untreated cells, while
clear tube formation was exhibited in VEGF-treated
control. Notably, EP treatment inhibited VEGF-induced
tube formation in a dose-dependent manner. Then, we
tested whether EP can affect VEGF-mediated STAT3
activation in HUVECs. As shown in Figure 4F, VEGF
treatment clearly enhanced phosphorylation of STAT3
in HUVECs, which was supported by Ebrahem’se v i -
dences [30]. In contrast, total STAT3 levels were not
significantly changed by the treatment of VEGF and/or
EP (Figure 4F).
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Figure 1 Ergosterol peroxide (EP) suppresses STAT3 activation in U266 cells. (A) Cells were treated with 25 μM EP for 0, 4, 8, 16 or 24 h.
(B) Cells were treated with various concentrations of EP (0, 6.25, 12.5 or 25 μM) for 8 h. (C) SCC4, DU145 and MDA-MB-231 cells were treated
with or without EP (25 μM) for 8 h. Whole cell extracts were prepared and subjected to Western blotting to determine level of phospho-STAT3
and STAT3. (D and E) Gel shift mobility assay was performed using nuclear extracts to examine the STAT3-DNA binding activity.
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To confirm the anti-tumor efficacy of EP, U266 cells
were subcutaneously inoculated into BALB/c athymic
nude mice in the flank area, and starting after 5 days
injection, the mice were administered EP or bortezomib
(a positive control) every 2-3 day with intraperitonial (i.
p.) injection. Tumor growth was monitored every other
day for 20 days. Tumor volumes in EP- or bortezomib-
treated groups were decreased compared with untreated
control (Figure 5A) without significant body weight loss
in EP-treated group (Figure 5B).
Consistently, immunohistochemistry showed that EP
treatment reduced the expression of phospho-STAT3
and angiogenesis marker CD34 compared to untreated
control (Figure 5C), implying the antitumor effect of
EP is associated with regulation of angiogenesis and
STAT3 in vitro and in vivo. In addition, TUNEL posi-
tive cells for apoptosis were effectively increased in
EP-treated tumor sections. However, considering that
EP treatment for 48 h or 72 h exerted significant cyto-
toxicity against U266 cells, we can postulate that EP
can exert antitumor effects via antiangiogenic activity
at low concentration and apoptotic activity at higher
concentration.
Discussion
Multiple myeloma, also called plasma cells myeloma, is
characterized by accumulation of secretory plasma cells.
For the treatment of multiple myeloma, various che-
motherapeutic agents such as vincristine, carmustine,
mephalan, cyclophosphamide, doxorubicin, prednisone
and dexamethasone have been used in combination or
either drug alone [31]. However, many multiple mye-
loma patients frequently had no response to these
agents and their prolonged exposure induced toxicity
even in normal cells. Recently, phytochemicals are con-
siderably advocated as rich sources of anti-cancer agents
that deserve more rigorous and valuable investigations.
Regarding this issue, several studies suggested phyto-
chemicals such as curcumin [14], resveratrol [32] and
capsaicin [33] as potent anti-cancer agents for multiple
myeloma treatment. We also found that genipin [34]
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Figure 2 Ergosterol peroxide (EP) inhibits phosphorylation of JAK2 and Src in U266 cells. Cells were treated with 25 μM EP for 0, 4, 8, 16
or 24 h. Whole cell extracts were prepared and subjected to Western blotting to determine level of (A) phospho-JAK2 and JAK2, adn (B)
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Figure 3 Ergosterol peroxide (EP) enhances expression of SHP-1 in U266 cells.( A )C e l l sw e r et r e a t e dw i t h2 5μME Pi nt h ea b s e n c eo r
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Figure 4 Ergosterol peroxide (EP) exerts anti-angiogenic activity in vitro. (A) U266 cells were treated with various concentrations of EP (0,
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of VEGF in the supernatants were measured by using a Quantikine VEGF ELISA kit. (E) For in vitro tube formation assay, HUVECs (3 × 10
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6 h. Cells were fixed with 2% paraformaldehyde, stained with 2% crystal violet, and the number of tube was randomly counted in selected areas
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loma therapy by inducing apoptosis and targeting the
signaling molecules such as STAT3.
The STAT proteins were identified for the last decade
as latent cytoplasmic transcription factors in response to
all cytokine driven signaling [15]. Seven mammalian
STAT proteins such as STAT1, 2, 3, 4, 5a, 5b and 6 act
as multifunctional mediators to regulate various cellular
p r o c e s s e ss u c ha sc e l lp r o l i f e ration, differentiation,
angiogenesis, and apoptosis [36]. Especially, STAT3 is
constitutively activated in many human cancers, includ-
ing prostate cancer [37], breast cancer [38], squamous
cell carcinoma of the head and neck (SCCHN) [39],
nasopharyngeal carcinoma and multiple myelomas [40].
Thus, STAT3 is considered as a valuable therapeutic
target molecule for cancer treatment.
Ergosterol peroxide (EP) is a steroid derivative isolated
from medicinal mushroom [41]. Several studies reported
anti-cancer activity of EP in various types of cancer
cells. For instance, Russo and colleagues reported that
EP attenuated cell growth and induced apoptosis in
human prostate cancer LNCaP and DU-145 cells [42].
Kobori and colleagues reported that EP suppressed
inflammatory response in RAW264.7 macrophages and
growth of HT29 colon adenocarcinoma cells [43]. Also,
Chen and colleagues suggested that EP from the fer-
mentation mycelia of Ganoderma lucidum cultivated in
the medium exerted the cytotoxic effect against Hep 3B
cells [44]. In the present study, we found that EP exerts
anti-cancer activity through the inhibition of angiogen-
esis by targeting the STAT3 signaling pathway in U266
cells in vitro and in vivo.
EP suppressed constitutive activation of STAT3 in
U266, SCC4, DU145 and MDA-MB-231 cells. EP also
inhibited the STAT3-DNA binding activity and the
nuclear translocation of STAT3, suggesting that EP can
prevent STAT3 activation at the transcriptional level.
The inhibitory effect of EP on STAT3 activation was
partly associated with the inhibition of upstream kinases
JAK2 and Src by EP treatment. Furthermore, protein
tyrosine phosphatases (PTPs) are known to be impli-
cated in STAT3 signaling, including SHP-1 [45], SHP-2
[46], PTEN [47], SOCS-1 [48] and so on. Our results
revealed that EP remarkably enhanced the expression of
SHP-1 at levels of protein and mRNA. In contrast, EP
had no significant effect on other PTPs such as SHP-2
and PTEN (data not shown). To confirm the signifi-
cance of SHP-1, we utilized PTP inhibitor pervanadate
or SHP-1 siRNA to block the expression of SHP-1. As
expected, EP failed to inhibit STAT3 activation in the
presence of pervanadate or SHP-1 siRNA, supporting
that SHP-1 plays a critical role in dephoshophorylating
STAT3 by EP in U266 cells.
Recently, Niu and colleagues reported that constitutive
activity of STAT3 up-regulated VEGF expression and
tumor angiogenesis [49]. Wei and colleagues also
reported that overexpression of constitutively activated
mutant STAT3 sufficiently increased VEGF expression
and tumor angiogenesis in vivo [50]. In contrast, domi-
nant negative STAT3 mutant inhibited VEGF expression
as well as angiogenesis. Additionally, it is of interest that
STAT3 activation by its upstream Src regulates VEGF
mediated angiogenesis and conversely blocking STAT3
inhibits Src-induced VEGF expression [51]. Consistently,
in the present study, EP significantly prevented VEGF-
induced phosphorylation of STAT3 as well as VEGF-
mediated tube formation in HUVECs, indicating anti-
angiogenic activity of EP by inhibiting STAT3 phos-
phorylation. Furthermore, we confirmed anti-tumor
effect of EP in mouse xenograft tumor model. Consis-
tent with the results of in vitro experiments, EP
decreased U266 tumor growth as well as suppressed the
expression levels of phospho-STAT3 and CD34 by
immunohistochemistry. Although there are evidences
that EP induces apoptosis at concentrations of 12.5-50
μM in LNCaP and DU-145 cells for 72 h [41,42,52], in
the current study, EP did not show any cytotoxicity
against U266 cells for 24 h up to 50 μM. Actually,
immunohistochemistry revealed that TUNEL positive
cells were increased in EP treated tumor sections, imply-
ing that EP can exert anti-angiogenic activity at non-
toxic concentrations and possibly induce apoptosis only
after long term culture or at high doses. Thus, mechan-
ism and pharmacokinetic studies with EP are still
required in vitro and in vivo to elucidate the relationship
between its anti-angiogenic and apoptotic activities at
different doses in the near future
Conclusions
Our findings demonstrate that EP can exert antitumor
activity in multiple myeloma U266 cells by anti-angio-
genic activity targeting JAK2/STAT3 signaling pathway
as a potent anti-cancer agent for multiple myeloma
treatment.
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